- Conditions
- Diabetes type1, Obesity
- Interventions
- Semaglutide Pen Injector, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 625–648
of 1,580
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 1 Diabetes
- Interventions
- Lantus and short acting analogs Vs NPH and short acting analogs
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 6 Years to 25 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hypoglycemia, Type 1 Diabetes
- Interventions
- Dasiglucagon
- Drug
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- Up to 5 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Fort Worth, Texas
- Conditions
- Type 1 Diabetes
- Interventions
- Social Media
- Behavioral
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 13 Years to 18 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- pioglitazone, Placebo control
- Drug
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
- Conditions
- Brittle Type 1 Diabetes Mellitus
- Interventions
- AT-1501 IV Infusion, Isolated cadaveric islet cells
- Biological
- Lead sponsor
- Eledon Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Lisofylline
- Drug
- Lead sponsor
- Eastern Virginia Medical School
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Insulin Treated Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 1
- Interventions
- Control:Diabetes mobile app
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Humalog, Novolog, BC222 insulin lispro, Bionic Pancreas
- Drug · Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 1 Diabetes
- Interventions
- Pramlintide
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 13 Years to 22 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma, Bile Duct Cancer
- Interventions
- Durvalumab, Tremelimumab, Trans-arterial Catheter Chemoembolization (TACE), Radiofrequency Ablation (RFA), Cryoablation
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Vitamin C, Vitamin E
- Dietary Supplement
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 8 Years to 15 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Allogenic Human Islet Cells, Gastrin 17
- Biological · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 68 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Complications
- Interventions
- Device specific training, Study clinician/educator visit
- Device · Other
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • The Bronx, New York
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Promoting Resilience in Stress Management (PRISM)
- Behavioral
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 13 Years to 18 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Houston, Texas • Seattle, Washington
- Conditions
- Diabetes, Type 1, Diabetes, Type 2
- Interventions
- Technosphere® Insulin Inhalation Powder, Usual Care
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 2,053 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 82
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 64 more
- Conditions
- Type 1 Diabetes
- Interventions
- Not listed
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 6 Years to 10 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Type 1 Diabetes
- Interventions
- Rapamycin, Mycophenolate Mofetil, Tacrolimus, Steroids
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2016
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Type 1 Diabetes
- Interventions
- AZD1656
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 20 Years to 65 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Diabetes, Type 1 Diabetes
- Interventions
- Daily feedback, Financial incentive
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 14 Years to 20 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Type 1 Diabetes Mellitus, Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY), MODY2 Diabetes, Healthy Volunteer
- Interventions
- Study Visit 1, Placebo, Study Visit 2, Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
- Procedure · Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Self-regulation, Medication Adherence
- Interventions
- Self-Regulation Intervention
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Not listed
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- cinnamon
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 13 Years to 18 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire